On January 7, 2024 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 corporate guidance and program updates (Press release, Ideaya Biosciences, JAN 7, 2024, View Source [SID1234639042]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
42nd Annual J.P. Morgan Healthcare Conference
Tuesday, January 9th, 2024 at 8:15 AM PT (11:15 AM ET)
Presentation by Yujiro S. Hata, Chief Executive Officer followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. Morgan
IDEAYA’s 2024 corporate guidance and program updates include:
Balance sheet of $511.1 million of cash, cash equivalents and marketable securities as of September 30, 2023, and $134.7 million estimated net proceeds from subsequent follow-on financing and $10 million receivable from GSK, is anticipated to fund operations into 2028
International site activation and double-digit patient enrollment achieved in potential registration-enabling Phase 2/3 clinical trial of darovasertib and crizotinib combination in first-line HLA-A2(-) metastatic uveal melanoma (MUM)
Clinical program update(s) in 2024 for potential registration-enabling Phase 2/3 clinical trial of darovasertib and crizotinib combination in first-line HLA-A2(-) MUM
Targeting clinical efficacy update from Phase 2 company sponsored neoadjuvant uveal melanoma (UM) study in mid-year 2024 and regulatory guidance update in 2024
Targeting ongoing enrollment of IDE397 and AMG 193 Phase 1 combination study in MTAP-deletion solid tumors and development of joint publication strategy in 2024
Anticipate First-Patient-In of Phase 1 IDE397 and Trodelvy clinical combination study in MTAP-deletion bladder cancer in mid-year 2024
Preliminary IDE397 clinical efficacy observed in MTAP deletion solid tumors, including RECIST 1.1 complete response in bladder cancer patient, 33% tumor shrinkage in NSCLC patient by CT/PET, and multiple ctDNA molecular responses in NSCLC and bladder cancer
Targeting IDE161 clinical program update(s) and enabling of clinical combination(s) in 2024
Preliminary IDE161 clinical efficacy observed in HRD solid tumors, including RECIST 1.1 partial responses in priority solid tumor types and >50% PSA reduction in a prostate cancer patient
Targeting ongoing enrollment of IDE161 Phase 1 expansion in HRD solid tumor priority types, including endometrial, colorectal, prostate, and ER+ HER2- breast cancers
Advancing Phase 1 dose escalation for GSK101 (IDE705) Pol Theta Helicase inhibitor, and targeting IND submission in 2024 for Werner Helicase Inhibitor Development Candidate ($7.0 million milestone upon IND clearance) under collaboration with GSK
Targeting multiple wholly-owned next generation development candidate nominations in 2024, including in MTAP-deletion, further advancing IDEAYA’s multi-pronged strategy in MTAP-deletion and AI/ML and structurally-enabled drug discovery platform
IDEAYA’s updated corporate presentation reflecting its 2024 corporate guidance is available on its website, at the Investor Relations page: View Source
A live audio webcast of the event, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at View Source A replay of available webcasts will be accessible for 30 days following the live event.